Nov 22, 2019: The U.S. Food and Drug Administration approved Aquestive Therapeutics’ treatment for neurological disorder amyotrophic lateral sclerosis (ALS).
According to the ALS Association, ALS is an ultra-rare neurodegenerative disorder that causes the death of neurons that controls the  voluntary muscles, in United States more than 6,000 people diagnosed with this disease.
- Advertisement -
Company’s Shares, which developed riluzole oral film (ROF) and will market the film with the brand name Exservan, rose 4% at $6.76 after the bell. https://kfgo.com/news/articles/2019/nov/22/fda-approves-aquestives-als-treatment/960323/
